Exacta AI processes real-time wet lab data and integrates it with knowledge from multiple sources to assess drug synergy, interactions, toxicity
Datar Cancer Genetics (DCG) has launched Exacta AI, a next-generation multi-analyte AI-driven platform providing optimised treatment options for cancer patients who have exhausted the standard options. It integrates a 360° tumour work-up and AI-assisted data analysis to decode complex tumour interactome data-including molecular (NGS: DNA+RNA), proteomic, genomic, functional, and clinical insights—providing personalised treatment options with thorough risk-benefit analysis.
Exacta AI processes real-time wet lab data and integrates it with knowledge from multiple sources to assess drug synergy, interactions, toxicity, and contraindications for Anti-body Drug Conjugates (ADC)s, Checkpoint Inhibitors (CPIs), targeted therapies, endocrine agents, chemotherapy agents and repurposed drugs. It can recommend up to 10 evidence-based multi-drug treatment combinations for evaluation by oncologists or molecular tumour boards (MTBs), offering new hope where no standard of care exists for refractory / recurrent cancer patients.
"For too long, we have been navigating through fragmented data streams, trying to make sense of multiple analytes without a structured framework. This AI-powered approach is poised to provide an integrated, evidence-based set of treatment options that can transform how we personalise cancer treatment," stated Dr Sewanti Limaye who is the Director of Medical and Precision Oncology at Sir HN Reliance Foundation Hospital, speaking at the recently held Datar Advisory Board Meeting in Mumbai.
"Exacta AI signifies a paradigm shift in the multi-omic analysis of tumors and the approach to treatment decision-making for complex cancer cases," asserts Dr Andy Gaya, Clinical Oncologist, Cromwell Hospital, London. "This next-generation technology provides an unprecedented level of therapy analysis in treatment selection that is aimed at improving patient outcomes while reducing avoidable exposure to ineffective therapies."
"Exacta AI represents a paradigm shift in how tumours are analysed and treatment planning is approached for complex cancer cases," says Dr Darshana Patil, Senior Director – Global Strategy and Medical Affairs. "When standard treatments fail, oncologists and MTBs face the daunting task of analyzing enormous amounts of data – from genetic mutations to protein expressions, from drug sensitivity to clinical trials – all while racing against time to make critical decisions. Exacta AI transforms this challenge into an opportunity for personalised medicine for patients who need it most."
"What makes Exacta AI truly unique is its ability to think like an entire team of multi-disciplinary experts, all at once," explains Dr Vineet Datta, Senior Director – Global Strategy and Business Development. "The platform processes information the way a molecular biologist, cancer cell expert, pharmacologist, and clinical oncologist would, only in minutes instead of several days. By applying rational scoring steps to analyse vast datasets, Exacta AI delivers highly refined interpretations, offering an unprecedented level of precision in generating treatment options."
